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Background: Strategies to identify high risk individuals who may 
develop lung cancer are sorely needed. Radiographic screening has 
several drawbacks including cost, high false positive rate, and exclu-
sion of never-smokers who account for up to 13% of new diagnoses. 
Sputum collection can be difﬁcult in up to half of former smokers. 
Alternatively, saliva is readily available and easy to collect. We have 
previously shown high sensitivity and speciﬁcity in distinguishing 
newly diagnosed oral squamous cell carcinoma from matched controls 
(Li et al. Clin Cancer Res 2004). Others have shown a correlation of 
salivary and serum levels of soluble Her2/neu in women with breast 
cancer compared to benign tumor and healthy controls (Streckfus et al. 
Clin Cancer Res 2000). These studies led us to embark on a pilot study 
to validate mRNA expression on a gene exon array platform and to ex-
plore gene exon signatures discriminating between early-stage NSCLC 
and healthy controls. 
Methods: Saliva is currently being collected from healthy subjects ages 
40-79, (current and former smokers [≥20 pack-year] and never-smokers 
[<100 cigarettes/lifetime] and histologically-conﬁrmed, untreated stage 
I-II NSCLC patients along with a medical history questionnaire. Exclu-
sion criteria included: active pulmonary infection within 6 months, ste-
roid inhaler use ≥ 6 months, or history of other invasive cancer within 
past 5 years. A one-time saliva specimen is being obtained between 9-
10 am to avoid diurnal variation, mixed with a RNA stabilization agent, 
and stored at -70˚C. RNA is then extracted, ampliﬁed, and hybridized 
to the Affymetrix Human Exon 1.0 arrays (which contain 1.4 million 
probe sets). Array data is analyzed after appropriate normalization. 
Results: As proof-of-principal of the value of the exon array discov-
ery platform, saliva mRNA expression was performed on 18 healthy 
subjects [14 males (3 never-smokers), 11 females (8 never-smokers)]. 
All of whom were able to provide adequate sample for analysis. Our 
data demonstrate that we have successfully ampliﬁed salivary RNA, 
hybridized to the exon array and have developed the statistical and 
informatics tools to harness the diagnostic information. Using these 
developed tools and the healthy cohort of subjects, we have identiﬁed 
and validated gender-speciﬁc salivary exon signatures.
Conclusions: Preliminary results with saliva mRNA exon-level expres-
sion proﬁling suggest that quality samples are easily obtainable and 
the technique is feasible. Updated results with NSCLC specimens will 
be presented. Supported by International Association for the Study of 
Lung Cancer Fellowship Award (GJW) and R01-DE15970-03 (DTW).
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Yiannakis, Dennis1 Lansdell, Kate1 Cassidy, Adrian2 Field, John2 
1 Plymouth Hospital NHS Trust, Plymouth, UK 2 The Roy Castle Foun-
dation, Liverpool, UK 
Background: Lung cancer is the most common cancer in the world, 
both in terms of incidence (1.35 million new cases, representing 12.4% 
of all new cancers) and mortality (1.18 million deaths, or 17.6% of the 
world total). Detection of lung cancer usually occurs late in the disease 
when it is beyond effective treatment and consequently, there is a high 
mortality rate. In clinically advanced tumour stages, long-term survival 
is rarely achieved with conventional cytotoxic agents. Therefore, the 
way forward for improved management and prognosis for individuals 
at high-risk lies with early detection of disease. 
Given that the causes of common cancers, such as lung cancer, may 
have their basis in environmental exposures occurring in the genetically 
predisposed host, it is essential that we study the interaction between 
lifestyle factors and susceptibility genes to produce a molecular-epi-
demiological risk assessment model. An epidemiological model has 
recently been developed by the Liverpool Lung Project (LLP) to select 
individuals at high risk of developing lung cancer. 
Aims: The Peninsula Lung Project will elucidate the role of lifestyle 
and environmental risk factors in determining speciﬁc acquired genetic 
alterations in the process leading to lung cancer, with the intention of 
developing a speciﬁc lung cancer risk assessment model for the Penin-
sula region of the UK. 
Methods: We plan to use the LLP molecular-epidemiological approach 
in a region of South West England (Peninsula), which differs from 
Liverpool in its demographic makeup. The study (which has ethical 
and NCRN approvals) will have a case-control design and will be 
conducted in 5 centres across the South West Peninsula. Each centre 
will recruit a group of newly diagnosed cases of lung cancer and a 
comparable group of either population or hospital controls. (Total: 
500 cases/1000 controls). Structured self-complete questionnaires will 
concentrate on obtaining details on lifestyle, residential history, medical 
history and occupational history over the whole life course. Whenever 
possible, place of residence will be mapped to local measures of air 
pollution. As well as tumour material from cases, samples of blood and 
oral scrapes will be collected both from cases and controls for methyla-
tion studies and SNIP analysis. Outcome data for all subjects will be 
collected.
Two controls will be selected for each case: control A will be matched 
to cases for age (± 2 years) and sex; control B will also be matched for 
smoking. 
Conclusion: This poster will expand on the objectives and methodol-
ogy of this (P-LLP) project, which will start in May 2007.
SCLC: Combined Modality Therapy
P1-202 SCLC: Combined Modality Therapy Posters, Mon, Sept 3 
Phase II study of Irinotecan (I) and carboplatin (C) with early 
concurrent radiotherapy (CR/RT) in limited-stage small cell lung 
cancer (LS-SCLC) patients (pts)
Domine, Manuel; Leon, Ana; Casado, Victoria; Rubio, Gustavo; 
Lopez-Gomez, Mirian; Arlanzon, Carmen; Ortega, Carolina; Ramirez, 
Natalia; Lobo, Francisco 
Servicio de Oncologia. Capio-Fundacion Jimenez Diaz. Universidad 
Autonoma de Madrid, Madrid, Spain
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS818
Background: Irinotecan (I) combined with Carboplatin (C) has proven 
to be an active combination in-patient with extensive stage SCLC. We 
conducted a prospective phase II study to determine the activity and 
safety of this combination with CT/RT in previously untreated LS-
SCLC pts. 
Patients and methods: The main objective was response rate (RR) and 
the secondary safety and overall survival. Eligibility included: measur-
able disease, ECOG PS 0-2, informed consent and adequate hepatic, 
renal and bone marrow function. Treatment consisted of: I 60mg/m2 IV 
followed for C AUC = 3 IV D1, 8 Q 21D for 6 cycles, and concurrent 
RT 2.0 Gy daily to a total of 60.0 Gy, beginning in the 2nd cycle. The 
dose of I and C was reduced to 50 mg/m2 and AUC: 2 respectively dur-
ing CT/RT (cycles: 2nd - 4th). Patients with complete response (CR) 
received PCI (2.0 Gy X 10) after completion chemotherapy.
Results: 30 pts were enrolled, 22 male and 8 female. Median age was 
71 years (range 43- 81); 76% had PS 0 or 1.
Twenty-eight pts were evaluable for response. The total number of 
cycles administered was 161 with a median of 6 (range 2-6). The rela-
tive dose-intensities of I and C were 84% and 87% respectively. The 
median of follow-up was 14 months. In intent to treat analysis the RR 
was 92.7%, twenty pts achieved a CR and 8 pts a PR. Median survival 
was 22 months. Grade 3-4 (NCI-CTC 3.0) toxicity (per cycle) included: 
neutropenia (14%), thrombocytopenia (14%), anemia (5%), diarrhea 
(12%), vomiting (5%). There were two episodes of typhitis and three 
episodes of febrile neutropenia, however there were no treatment-re-
lated deaths. 
Conclusions: IC combined with early CR/RT is highly active with a 
favorable median survival. The proﬁle of safety is adequate in pts with 
LS-SCLC. Further development of this combination is warranted. 
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Background: Patients with limited disease SCLC were treated up till 
2001 with sequential chemoradiotherapy (SCT) and from 2001 with 
concurrent chemoradiotherapy (CCT). The optimal treatment has yet 
to be deﬁned. This retrospective study analysed the efﬁcacy of both 
treatments. 
Methods: Between 1991 until December 2000, 69 SCT pts were in-
cluded, and from 2001 until February 2005 40 pts who underwent CCT.
In SCT, the chemotherapy consisted of 5 cycles of cyclophosphamide, 
doxorubicin and etoposide. In case of complete remission, radiotherapy 
was given in once-daily fractions of 2.5 Gy, 5 fractions/week, to a total 
dose of 40 Gy. Prophylactic cranial irradiation (PCI) was given in 15 
fractions of 2 Gy, 5 fractions/week.
In CCT, radiotherapy was started on day 22 after start chemotherapy. 
The fraction dose was 1.8 Gy, 5 fractions/week, the total dose was 45 
Gy. Chemotherapy consisted of 4 or 5 cycles of cisplatin and etopside. 
PCI was applied to patients who had achieved a complete response. 
Primary endpoints are radiological response, median survival time and 
3- and 4-year overall survival; secondary endpoints include causes of 
death, frequency of metastases and toxicity.
The Kaplan-Meier method was applied to determine the median sur-
vival time and the survival rates. 
Results: The mean and median tumour volume of SCT pts was 142 
and 81cm3, those of CCT pts 117.6 and 40 cm3, resp. The mean overall 
treatment time of SCT was 182 d, and that of CCT 89 d.
The radiological complete response of SCT pts was 95.6%, of pts with 
CCT 60%. PCI was applied to 95.6% of the SCT pts and to 57.5% of 
the CCT pts. 
The SCT median survival time was 24.9±3.0 month; the 3- and 4-year 
overall survival were 38.8±6.1 and 31.5±6.0%, respectively. The CCT 
median survival time was 23.8±4.2 month and the 3- and 4-year overall 
survival 36.7±8.3 and 31.5±8.6 %, respectively.
Of the 69 SCT pts, 51 had died of which 38 pts (74.5%) with tumour 
and 21 of 24 CCT pts (87.5%). 
Grade3/4 haematological side effects were reported in 47 (68%) SCT 
pts and in 18 (45%) CCT pts.
Symptomatic radiation oesophagitis was observed in 41 (59%) of SCT 
pts and in 19 (47.5%) of the CCT pts. 
Brain metastases were diagnosed in 12 (17%) SCT pts and in 13 
(32.5%) CCT pts. 
The mean interval time for SCT pts between restaging after chemo-
therapy and start of radiotherapy was 52.3 d, the median 47 d, and the 
range 21-173 d.
Conclusions: Although a higher mean and median tumour volume, a 
better radiological response was obtained for the SCT pts. The median 
survival time and the 3- and 4-y survival rates were not signiﬁcantly 
different. The frequency of brain metastases in CCT pts was twice of 
that of SCT pts.
We advise to perform a prospective randomised trial comparing SCT 
and CCT. Better results might be expected with SCT schemes for 
smaller tumour volumes and a smaller interval time between end of 
chemo- and start of radiotherapy.
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SCLC represents about 20% of LC patients in most developed 
countries, it has poor prognosis with 10% survival at 2 years. In this 
retrospective study there were 80(6%) patients with SCLC among 
1274 LC patients admitted to the INT between 1994-2001. Four cases 
had incomplete data. We analyzed the prognostic factors, treatment, 
outcome and survival of the 76 cases; 63 with Limited Disease (L.D) 
and 13 with Extended Disease (E.D). Twelve (16%) patients did not 
experience weight loss and 25(33%) patients (27% in LD and 62% in 
ED) lost more than 10% in six months. Karnofski PS (KPS) less than 
70% had 25 (33%) patients (30% with L.D and 46% with E.D) 
From the 32 (42%) patients who received chemoradiotherapy (CTRT) 
(Cisplatin Etoposide and RT) in other oncology institutions, median 
